Subscribe to Newsletter

Search

Reset Filter

4128 search results for ‘*’

Manufacture Bioprocessing - Upstream & Downstream

The Pandemic Impact: Focusing on Security of Supply in Pharma

| Sponsored by Cytiva

Cytiva is transforming in the wake of COVID-19 – but what lessons can the wider biopharma industry take forward?

Discovery & Development Formulation

The Future of LNP Formulation technology for Pharma is Here

| Sponsored by KNAUER

More researchers are exploring the potential of mRNA encapsulation into lipid nanoparticles.

Manufacture Bioprocessing - Upstream & Downstream

April’s Top Biopharma Headlines

What happened in April in the biopharma industry? Here’s our roundup of the biggest headlines and research.

Business & Regulation Advanced Medicine

Champions of Cell and Gene Therapy

| Angus Stewart

In our second C+G Champions installment, we ask industry leaders in the cell and gene field to answer key questions about the industry.

CHO Platform Service Package: The Fast Track to IND

| Contributed by Sartorius

The CHO Platform Service package combines Sartorius’ technologies and services as one integrated solution that accelerates your program

Ploughshare® Mixer for batch operation in pharmaceutical production: well-established all-rounder

| Contributed by Lodige

The advantages of a horizontal Ploughshare® Mixer used lie in the short mixing time with the highest mixing precision in the 1:100,000 range

Discovery & Development Drug Discovery

The Final Frontier for Regenerative Medicine

| Stephanie Vine

What will drug development look like aboard a new commercial space station?

Discovery & Development Analytical Science

Meet the Trendsetting Techniques of Biotherapeutic Molecule Characterization

| Eliza Lee

Advanced analytical technologies now offer the detailed assessments biopharma drug developers need.

OneXpress™ Solution for Accelerating Dose Form Development to Commercialization

| Contributed by Catalent

Catalent’s OneXpress™ solution combines phase-appropriate scale and technologies with expertise across diverse dose forms to accelerate drug programs

Business & Regulation Business Practice

Time to Shine

| Maryam Mahdi

What do companies need to consider when developing next-gen medicines for rare diseases?

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register